An interventional study of Somnomat - rocking bed providing vestibular stimulation during sleep in Memory Deficit Aquired Due to the Disease, e.g. Stroke, Neurodegeneration, Inflammatory Disease of CNS, Traumatic Brain Injury, sponsored by Cereneo AG. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by Cereneo AG · Not applicable, Interventional, and Treatment
What do you have to do if you decide to participate?
Participation in this study will take 4-6 weeks depending on your group. All study assess-ments will be done during your stay in the clinic. If you agree to participate, you will be asked to:
Risks
The investigational rocking bed has not yet been certified in Switzerland. Its use for neurorehabilitation patients is new and has not yet been tested. We may not yet know all the possible risks and side effects of the tested device. So far, the following risks and discomforts should be considered:
132 studies on the registry are indexed under Nerve Degeneration; 54 are open to participants now.
This study's planned enrollment of 20 is below the median of 50 across 73 interventional studies indexed under Nerve Degeneration.
Browse Nerve Degeneration studies →Cereneo AG is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants of Group 1 will be using the rocking bed for the first 2 weeks after randomization.
Device: Somnomat - rocking bed providing vestibular stimulation during sleep
Participants of Group 2 will be using the rocking bed in weeks 3-4 after randomization
Device: Somnomat - rocking bed providing vestibular stimulation during sleep
Rocking is known to have a sedative and sleep-promoting effect: parents are rocking their newborns and infants to facilitate sleep, and many individuals experience increased sleepiness during passive motion, such as in transport. Recent engineering solutions have enabled the development of rocking beds and wearable devices simulating motion. Previous studies of rocking bed in healthy humans have shown that the use of these devices can improve sleep. Furthermore, improvement of sleep can mediate positive effects of rocking on memory, learning. However, their safety, effectiveness and applicability should be tested in research and clinical setting In this study, we are therefore investigating whether the rocking bed is efficient for sleep, if it has complementary effects on memory while using together with the cognitive training. In addition we are testing, if the device is well tolerated. The investigational device is not yet approved in Switzerland.
Objective total sleep time (TST)
measured with polysomnography
Time frame: Objective sleep measures (PSG) are obtained pre- and post-intervention phases at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.
objective sleep efficiency (SE)
measured by PSG
Time frame: Objective sleep measures (PSG) are obtained pre- and post-intervention phases at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.
objective sleep latency (SL)
measured by PSG
Time frame: Objective sleep measures (PSG) are obtained pre- and post-intervention phases at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.
objective wake after sleep onset (WASO)
measured by PSG
Time frame: Objective sleep measures (PSG) are obtained pre- and post-intervention phases at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.
total time in bed (TIB)
measured by PSG
Time frame: Objective sleep measures (PSG) are obtained pre- and post-intervention phases at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.
Objective number of awakenings
measured by PSG
Time frame: Objective sleep measures (PSG) are obtained pre- and post-intervention phases at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.
absolute duration of N1
obtained from PSG, measured in min
Time frame: Objective sleep measures (PSG) are obtained pre- and post-intervention phases at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.
proportion of N1
obtained from PSG, measured in %
Time frame: obtained pre- and post-intervention phases at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.
absolute duration of N2
obtained from PSG, measured in min
Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.
Proportion of N2
obtained from PSG, measured in %
Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.
absolute duration of N3 stage
obtained from PSG, measured in min
Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.
Proportion of N3 stage
obtained from PSG
Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.
absolute duration of REM phase
obtained from PSG, measured in min
Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.
Proportion of REM phase
obtained from PSG, measured in %
Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.
Total number of sleep spindles
obtained from PSG, countable variable
Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.
Density of sleep spindles
obtained from PSG, index calculated as number of events per 1 h in N2 stage
Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.
Slow wave activity
obtained from PSG, power of delta activity per unit of time
Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.
subjective sleep effectiveness
obtained from a daily sleep diary, measured in %
Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0-4 for Group 1 and Week 0-6 for Group 2.
subjective sleep latency
obtained from daily sleep diary
Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0-4 for Group 1 and Week 0-6 for Group 2.
subjective total sleep time
obtained from daily sleep diary
Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0-4 for Group 1 and Week 0-6 for Group 2.
Subjective number of awakenings
obtained from daily sleep diary
Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0-4 for Group 1 and Week 0-6 for Group 2.
subjective wake after sleep onset (WASO)
obtained from daily sleep diary
Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0-4 for Group 1 and Week 0-6 for Group 2.
PSQI score
Pittsburgh Sleep Quality Index (PSQI), a validated self-report measure of sleep quality over the past month. The PSQI yields a global score (0-21), with higher scores indicating poorer sleep quality.
Time frame: subjective sleep quality are obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.
Verbal memory
Neuropsychological test: Auditiv-Verbaler Lern- und Gedächtnistest (AVLGT) for German-speaking participants, or its English adaptation, Verbal Learning and memory test (VLMT) the consisting of 15 words with different word lists in order to avoid learning effect. Assessments are conducted weekly
Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: between Week 0 and Week 4 for Group 1 and between Week 0 and Week 6 for Group 2.
Age
measured in years
Time frame: Collected at baseline (Week 0) between 03.08.2026 and 31.07.2027
Gender
Time frame: Collected at baseline (Week 0) between 03.08.2026 and 31.07.2027
Race
categorical variable
Time frame: Collected at baseline (Week 0) between 03.08.2026 and 31.07.2027
Years of education
measured in years
Time frame: Collected at baseline (Week 0) between 03.08.2026 and 31.07.2027
Main diagnosis
Time frame: Collected at baseline (Week 0) between 03.08.2026 and 31.07.2027
Disease onset
years ago
Time frame: Collected once at baseline (Week 0) between 03.08.2026 and 31.07.2027
comorbid sleep disordes
categorical variable
Time frame: Collected at baseline (Week 0) between 03.08.2026 and 31.07.2027
Medications
categorical variable
Time frame: Collected at baseline (Week 0) between 03.08.2026 and 31.07.2027
Plan to share: No — There is not a plan to make IPD available
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cereneo AG